Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium

Marc Fenster, Quazim A. Alayo, Aava Khatiwada, Wenfei Wang, Christina Dimopoulos, Alexandra Gutierrez, Matthew A. Ciorba, George P. Christophi, Robert P. Hirten, Christina Ha, Poonam Beniwal-Patel, Benjamin L. Cohen, Gaurav Syal, Andres Yarur, Anish Patel, Jean Frederic Colombel, Joel Pekow, Ryan C. Ungaro, David T. Rubin, Parakkal Deepak

Research output: Contribution to journalShort surveypeer-review

9 Scopus citations

Abstract

The safety and efficacy of tofacitinib in Crohn's disease (CD) has been studied in 2 phase II trials in patients with moderate-to-severe CD with no new safety signals observed, but no significant difference from placebo in the primary efficacy endpoint of clinical response.1–3 However, post hoc analyses and smaller studies have observed clinical and biologic response to tofacitinib in patients with CD.2,4,5 There is a paucity of real-world effectiveness and safety data for tofacitinib in non–Food and Drug Administration label usage in patients with CD and patients with inflammatory bowel disease–unclassified (IBD-U).

Original languageEnglish
Pages (from-to)2207-2209.e3
JournalClinical Gastroenterology and Hepatology
Volume19
Issue number10
DOIs
StatePublished - Oct 2021

Fingerprint

Dive into the research topics of 'Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium'. Together they form a unique fingerprint.

Cite this